Temporal and regional expression changes and co‐staining patterns of metabolic and stemness‐related markers during glioblastoma progression

Abstract

AbstractGlioblastomas (GBMs) are characterized by high heterogeneity, involving diverse cell types, including those with stem‐like features contributing to GBM's malignancy. Moreover, metabolic alterations promote growth and therapeutic resistance of GBM. Depending on the metabolic state, antimetabolic treatments could be an effective strategy. Against this background, we investigated temporal and regional expression changes and co‐staining patterns of selected metabolic markers [pyruvate kinase muscle isozyme 1/2 (PKM1/2), glucose transporter 1 (GLUT1), monocarboxylate transporter 1/4 (MCT1/4)] in a rodent model and patient‐derived samples of GBM. To understand the cellular sources of marker expression, we also examined the connection of metabolic markers to markers related to stemness [Nestin, Krüppel‐like factor 4 (KLF4)] in a regional and temporal context. Rat tumour biopsies revealed a temporally increasing expression of GLUT1, higher expression of MCT1/4, Nestin and KLF4, and lower expression of PKM1 compared to the contralateral hemisphere. Patient‐derived tumours showed a higher expression of PKM2 and Nestin in the tumour centre vs. edge. Whereas rare co‐staining of GLUT1/Nestin was found in tumour biopsies, PKM1/2 and MCT1/4 showed a more distinct co‐staining with Nestin in rats and humans. KLF4 was mainly co‐stained with GLUT1, MCT1 and PKM1/2 in rat and human tumours. All metabolic markers yielded individual co‐staining patterns among themselves. Co‐staining mainly occurred later in tumour progression and was more pronounced in tumour centres. Also, positive correlations were found amongst markers that showed co‐staining. Our results highlight a link between metabolic alterations and stemness in GBM progression, with complex distinctions depending on studied markers, time points and regions.